Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Forst

Showing results (101-110 of 148) with videos related to

Pageof 15
Sort By:
PPAR Research|August 3, 2011
Downregulation of the proinflammatory state of circulating mononuclear cells by short-term treatment with pioglitazone in patients with type 2 diabetes mellitus and coronary artery diseaseAndreas Pfützner, Alexander Weise, Elisabeth Pfützner-Riehn, et al.
Journal of Diabetes Science and Technology|May 31, 2014
Retinal Microcirculation in Type 1 Diabetic Patients With and Without Peripheral Sensory NeuropathyThomas Forst, Matthias M Weber, Michael Mitry, et al.
Diabetes Technology & Therapeutics|April 5, 2011
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemiaAndreas Pfützner, Thomas Schöndorf, Diethelm Tschöpe, et al.
Endocrinology, Diabetes & Metabolism|November 29, 2025
Type 1 Diabetes and Other Autoimmune Diseases-Epidemiology, Pathophysiology and ScreeningGeorge J Kahaly, Thomas Forst, Monika Kellerer, et al.
Tropical Medicine & International Health : TM & IH|December 20, 2005
Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern GhanaSusanne Röwer, Ulrich Bienzle, Alexander Weise, et al.
Journal of Diabetes Science and Technology|November 6, 2009
Increased arterial augmentation and augmentation index as surrogate parameters for arteriosclerosis in subjects with diabetes mellitus and nondiabetic subjects with cardiovascular diseaseBirgit Wilhelm, Johannes Klein, Christiane Friedrich, et al.
Diabetes Care|October 8, 2009
Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetesThomas Forst, Andreas Pfützner, Frank Flacke, et al.
Diabetes Care|April 9, 2013
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)Matthew C Riddle, Thomas Forst, Ronnie Aronson, et al.
Microcirculation (New York, N.Y. : 1994)|October 7, 2005
Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2Thomas Forst, Georg Lübben, Clothilde Hohberg, et al.
Diabetes Technology & Therapeutics|February 3, 2005
IRIS II Study: Sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistanceMatthias R Langenfeld, Thomas Forst, Eberhard Standl, et al.
Pageof 15

Showing results (101-110 of 148) with videos related to

Sort By:
Pageof 15
PPAR Research|August 3, 2011
Downregulation of the proinflammatory state of circulating mononuclear cells by short-term treatment with pioglitazone in patients with type 2 diabetes mellitus and coronary artery diseaseAndreas Pfützner, Alexander Weise, Elisabeth Pfützner-Riehn, et al.
Journal of Diabetes Science and Technology|May 31, 2014
Retinal Microcirculation in Type 1 Diabetic Patients With and Without Peripheral Sensory NeuropathyThomas Forst, Matthias M Weber, Michael Mitry, et al.
Diabetes Technology & Therapeutics|April 5, 2011
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemiaAndreas Pfützner, Thomas Schöndorf, Diethelm Tschöpe, et al.
Endocrinology, Diabetes & Metabolism|November 29, 2025
Type 1 Diabetes and Other Autoimmune Diseases-Epidemiology, Pathophysiology and ScreeningGeorge J Kahaly, Thomas Forst, Monika Kellerer, et al.
Tropical Medicine & International Health : TM & IH|December 20, 2005
Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern GhanaSusanne Röwer, Ulrich Bienzle, Alexander Weise, et al.
Journal of Diabetes Science and Technology|November 6, 2009
Increased arterial augmentation and augmentation index as surrogate parameters for arteriosclerosis in subjects with diabetes mellitus and nondiabetic subjects with cardiovascular diseaseBirgit Wilhelm, Johannes Klein, Christiane Friedrich, et al.
Diabetes Care|October 8, 2009
Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetesThomas Forst, Andreas Pfützner, Frank Flacke, et al.
Diabetes Care|April 9, 2013
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)Matthew C Riddle, Thomas Forst, Ronnie Aronson, et al.
Microcirculation (New York, N.Y. : 1994)|October 7, 2005
Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2Thomas Forst, Georg Lübben, Clothilde Hohberg, et al.
Diabetes Technology & Therapeutics|February 3, 2005
IRIS II Study: Sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistanceMatthias R Langenfeld, Thomas Forst, Eberhard Standl, et al.
Pageof 15